Trudel, S., Seval, G. C., Delimpasi, S., Vorobyev, V. I., Quach, H., Špička, I., Radocha, J., Koh, Y., Robak, P., Fuente, F. D. A. D. L., García, E. G., Mangiacavalli, S., Polinkovsky, M., Ma, J., Moore, A., Brock, K., Grams, J., Manasanch, E., Mateos, M., Dimopoulos, M. A. (2026). Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7515